Nirogacestat Approval Offers Choice to Desmoid Tumor Population

Commentary
Video

The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.

In an interview with CancerNetwork®, Brain Van Tine, MD, PhD, spoke about how the FDA approval of nirogacestat (Ogsiveo) in progressing desmoid tumors may offer patients a choice when it comes to managing their disease.1

Van Tine, a professor of medicine in the Division of Oncology, Section of Medical Oncology at Washington University School of Medicine’s Siteman Cancer Center, discussed how nirogacestat may have a different adverse effect (AE) profile compared with sorafenib (Nexavar), which may produce rashes and some nausea. Although nirogacestat may cause ovarian failure in some younger female patients, he stated that this wouldn’t be a concern in male patients or those who have undergone menopause. He continued to say that nirogacestat’s approval will allow for patients to decide which agent would be more suitable for them as part of a patient-centered discussion.

Supporting data for the approval of nirogacestat came from the phase 3 DeFi trial (NCT03785964), in which the agent elicited a statistically significant progression-free survival (PFS) benefit compared with placebo in those with desmoid tumors (HR, 0.29; 95% CI, 0.15-0.55; P <.001).2

Transcript:

I think the most important thing that comes out of having a second active drug and the first FDA-approved drug for the treatment of desmoid tumors is that patients actually have choices. The [adverse] effect profile of these two drugs is different.

Sorafenib is a drug that you have to use carefully because [patients] can get rashes on [their] hands and feet; you have some tolerance for nausea and some tolerance for fatigue. Nirogacestat has a different adverse effect profile and some things you have to watch for. Overall, it is something that may be more appealing to the average patient. There is some concern that this can induce ovarian failure in younger women, but for older women and male patients, this is not a concern. There may be a selective advantage for one drug over the other depending on a patient-centered discussion of which drug they'd like to try. The biggest thing that comes out of an FDA approval here is actually choice.

References

  1. FDA approves nirogacestat for desmoid tumors. News release. FDA. November 27, 2023. Accessed November 27, 2023. https://tinyurl.com/3zezwe53
  2. Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388:898-912. doi:10.1056/NEJMoa2210140
Recent Videos
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
CAR T-cell therapies or other agents that impact the immune system in the long term may be important to keep in mind for the management of SCLC.
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Patients with mantle cell lymphoma who are older and have less fitness may be eligible for regimens that include bendamustine/rituximab.
Employing patient-reported outcomes may help include those with small cell lung cancer in the shared decision-making process.
Related Content